Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Cells in Matrix

Financiado

Cerrado

Cells in Matrix an innovative 3D model for R D of Diabetes

The demand for diabetes drugs keeps increasing as adult Diabetes prevalence reached 425 million people in 2017 (1 in 11 adults) and is estimated to rise to 629 million till 2045. The market of Diabetes drugs is expected to reach €... ver más

28/02/2023

Betalin Therapeuti...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

BETALIN THERAPEUTICS LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 6 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-02-28

EIC-FTI-2018-2020: Fast Track to Innovation (FTI)

I+D

Cerrada hace 6 años

0% 79% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

6 Participantes

Betalin Therapeutics

1.23M€ | Lider

COSFER

FRIOBAS BASILIO,

246.33K€ | Participante

SIMON MARTIN GUIJUELO

203.21K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

DELIVER DELIVERy of advanced therapies for diabetes training network 2M€ Cerrado

DiogenX Beta-cell recovery to counter diabetes 6M€ Cerrado

Micro Pancreas Cure Diabetes by Injection of Micro Pancreas Cell Therapy 4M€ Cerrado

PCI2024-153423 Herramientas diagnósticas, pronósticas y terapéuticas 315K€ Cerrado

PTQ-09-02-01241 Descubrimiento y desarrollo de medicamentos antidiabeticos m... 56K€ Cerrado

ORBITO Oral biopharmaceutics tools 25M€ Cerrado

Duración del proyecto: 36 meses Fecha Inicio: 2020-02-21
Fecha Fin: 2023-02-28

Líder del proyecto

BETALIN THERAPEUTICS LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The demand for diabetes drugs keeps increasing as adult Diabetes prevalence reached 425 million people in 2017 (1 in 11 adults) and is estimated to rise to 629 million till 2045. The market of Diabetes drugs is expected to reach €80.5 Billion in 2019 while the investment in Diabetes drug development is ~ €4 Billion (CAGR of 13%). There is a constant need for more effective diabetes medications, hampered by the poor predictability of the current systems for identification of lead compounds during drug discovery. The failure rate of new drugs development is about 90% and the cost for reaching the market with a new drug is ~ €1 Billion. Cells in Matrix Project develops an innovative 3D model for R&D of Diabetes Drugs , an Engineered Micro Pancreas (EMP) based on organ-derived 3D cell culture and human sourced insulin producing cells as an innovative tool for accelerating and cost reduction of Diabetes drug development. EMP system offers significantly extended shelf life and function for in-depth studies of drug molecules mode of action, validation, toxicology and in vitro pharmacokinetics, rendering higher prediction reliability. Cells in Matrix disruptive technology creates market added value to all the stakeholders, especially pharma industry, by improving compound screening at least X4 (from 5% rate of success today to at least 20%), resulting in cost saving that could reach €100 million per innovative new drug development. The project receives strong interest from stakeholders and plans immediate commercialization of the product to direct endusers, including academia and pharma companies, such as Boehringer Ingelheim. The FTI funding will enable market entry and validation & support external fundraising for the wider penetration of the global drug discovery market. Betalin Therapeutics and Kugelmeiers, the project commercial leading partners will share the growth and revenues gained by its commercial success.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores